Phase I/II Trial of Adeno-Associated Virus–Mediated Alpha-Glucosidase Gene Therapy to the Diaphragm for Chronic Respiratory Failure in Pompe Disease: Initial Safety and Ventilatory Outcomes
Abstract
Pompe disease is an inherited neuromuscular disease caused by deficiency of lysosomal acid alpha-glucosidase (GAA) leading to glycogen accumulation in muscle and motoneurons. Cardiopulmonary failure in infancy leads to early mortality, and GAA enzyme replacement therapy (ERT) results in improved survival, reduction of cardiac hypertrophy, and developmental gains. However, many children have progressive ventilatory insufficiency and need additional support. Preclinical work shows that gene transfer restores phrenic neural activity and corrects ventilatory deficits. Here we present 180-day safety and ventilatory outcomes for five ventilator-dependent children in a phase I/II clinical trial of AAV-mediated GAA gene therapy (rAAV1-hGAA) following intradiaphragmatic delivery. We assessed whether rAAV1-hGAA results in acceptable safety outcomes and detectable functional changes, using general safety measures, immunological studies, and pulmonary functional testing. All subjects required chronic, full-time mechanical ventilation because of respiratory failure that was unresponsive to both ERT and preoperative muscle-conditioning exercises. After receiving a dose of either 1×1012 vg (n=3) or 5×1012 vg (n=2) of rAAV1-hGAA, the subjects' unassisted tidal volume was significantly larger (median [interquartile range] 28.8% increase [15.2–35.2], p<0.05). Further, most patients tolerated appreciably longer periods of unassisted breathing (425% increase [103–851], p=0.08). Gene transfer did not improve maximal inspiratory pressure. Expected levels of circulating antibodies and no T-cell-mediated immune responses to the vector (capsids) were observed. One subject demonstrated a slight increase in anti-GAA antibody that was not considered clinically significant. These results indicate that rAAV1-hGAA was safe and may lead to modest improvements in volitional ventilatory performance measures. Evaluation of the next five patients will determine whether earlier intervention can further enhance the functional benefit.
Get full access to this article
View all available purchase options and get full access to this article.
References
Allen J.2010. Pulmonary complications of neuromuscular disease: a respiratory mechanics perspectivePaediatr. Respir. Rev.1118-23. Allen, J. (2010). Pulmonary complications of neuromuscular disease: a respiratory mechanics perspective. Paediatr. Respir. Rev. 11, 18–23.
American Thoracic Society/European Respiratory Society2002. ATS/ERS Statement on respiratory muscle testingAm. J. Respir. Crit. Care Med.166518-624. American Thoracic Society/European Respiratory Society. (2002). ATS/ERS Statement on respiratory muscle testing. Am. J. Respir. Crit. Care Med. 166, 518–624.
Baydur A.Kanel G.2003. Tracheobronchomalacia and tracheal hemorrhage in patients with Duchenne muscular dystrophy receiving long-term ventilation with uncuffed tracheostomiesChest1231307-1311. Baydur, A., and Kanel, G. (2003). Tracheobronchomalacia and tracheal hemorrhage in patients with Duchenne muscular dystrophy receiving long-term ventilation with uncuffed tracheostomies. Chest 123, 1307–1311.
Bolton C.F.Grand'Maison F.Parkes A.Shkrum M.1992. Needle electromyography of the diaphragmMuscle Nerve15678-681. Bolton, C.F., Grand'Maison, F., Parkes, A., and Shkrum, M. (1992). Needle electromyography of the diaphragm. Muscle Nerve 15, 678–681.
Brantly M.L.Spencer L.T.Humphries M. et al.2006. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adultsHum. Gene Ther.171177-1186. Brantly, M.L., Spencer, L.T., Humphries, M., et al. (2006). Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum. Gene Ther. 17, 1177–1186.
Brantly M.L.Chulay J.D.Wang L. et al.2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyProc. Natl. Acad. Sci. U. S. A.10616363-16368. Brantly, M.L., Chulay, J.D., Wang, L., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U. S. A. 106, 16363–16368.
Burrow T.A.Bailey L.A.Kinnett D.G.Hopkin R.J.2010. Acute progression of neuromuscular findings in infantile Pompe diseasePediatr. Neurol.42455-458. Burrow, T.A., Bailey, L.A., Kinnett, D.G., and Hopkin, R.J. (2010). Acute progression of neuromuscular findings in infantile Pompe disease. Pediatr. Neurol. 42, 455–458.
Chakrapani A.Vellodi A.Robinson P. et al.2010. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experienceJ. Inherit. Metab. Dis.33747-750. Chakrapani, A., Vellodi, A., Robinson, P., et al. (2010). Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J. Inherit. Metab. Dis. 33, 747–750.
Depalo V.A.McCool F.D.2002. Respiratory muscle evaluation of the patient with neuromuscular diseaseSemin. Respir. Crit. Care Med.23201-209. Depalo, V.A., and McCool, F.D. (2002). Respiratory muscle evaluation of the patient with neuromuscular disease. Semin. Respir. Crit. Care Med. 23, 201–209.
DeRuisseau L.R.Fuller D.D.Qiu K. et al.2009. Neural deficits contribute to respiratory insufficiency in Pompe diseaseProc. Natl. Acad. Sci. U. S. A.1069419-9424. DeRuisseau, L.R., Fuller, D.D., Qiu, K., et al. (2009). Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc. Natl. Acad. Sci. U. S. A. 106, 9419–9424.
Dhand U.K.2006. Clinical approach to the weak patient in the intensive care unitRespir. Care511024-1040discussion 1040–1041. Dhand, U.K. (2006). Clinical approach to the weak patient in the intensive care unit. Respir. Care 51, 1024–1040; discussion 1040–1041.
DiMattia M.A.Nam H.J.Van Vliet K. et al.2012. Structural insight into the unique properties of adeno-associated virus serotype 9J. Virol.866947-6958. DiMattia, M.A., Nam, H.J., Van Vliet, K., et al. (2012). Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947–6958.
Domenech-Clar R.Lopez-Andreu J.A.Compte-Torrero L. et al.2003. Maximal static respiratory pressures in children and adolescentsPediatr. Pulmonol.35126-132. Domenech-Clar, R., Lopez-Andreu, J.A., Compte-Torrero, L., et al. (2003). Maximal static respiratory pressures in children and adolescents. Pediatr. Pulmonol. 35, 126–132.
Elmallah M.K.Falk D.J.Federico R.-A. et al.2012. Persistent correction of hypoglossal motoneuron enzyme deficiency following gene delivery to the tongue in a mouse model of Pompe diseaseSociety for NeuroscienceNew Orleans, LAOnline. Elmallah, M.K., Falk, D.J., Federico, R.-A., et al. (2012). Persistent correction of hypoglossal motoneuron enzyme deficiency following gene delivery to the tongue in a mouse model of Pompe disease. (Society for Neuroscience, New Orleans, LA). Online.
Falk D.J.Mah C.S.Soustek M.S. et al.2013. Intrapleural administration of AAV9 reverses neural and cardiorespiratory dysfunction in Pompe diseaseMol. Ther.(in press). Falk, D.J., Mah, C.S., Soustek, M.S., et al. (2013). Intrapleural administration of AAV9 reverses neural and cardiorespiratory dysfunction in Pompe disease. Mol. Ther. (in press).
Ferrari A.Ferrara C.Balugani M.Sassi S.2010. Severe scoliosis in neurodevelopmental disabilities: clinical signs and therapeutic proposalsEur. J. Phys. Rehabil. Med.46563-580. Ferrari, A., Ferrara, C., Balugani, M., and Sassi, S. (2010). Severe scoliosis in neurodevelopmental disabilities: clinical signs and therapeutic proposals. Eur. J. Phys. Rehabil. Med. 46, 563–580.
Fukuda T.Ewan L.Bauer M. et al.2006. Dysfunction of endocytic and autophagic pathways in a lysosomal storage diseaseAnn. Neurol.59700-708. Fukuda, T., Ewan, L., Bauer, M., et al. (2006). Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann. Neurol. 59, 700–708.
Gambetti P.Dimauro S.Baker L.1971. Nervous system in Pompe's disease. Ultrastructure and biochemistryJ. Neuropathol. Exp. Neurol.30412-430. Gambetti, P., Dimauro, S., and Baker, L. (1971). Nervous system in Pompe's disease. Ultrastructure and biochemistry. J. Neuropathol. Exp. Neurol. 30, 412–430.
Harikumar G.Moxham J.Greenough A.Rafferty G.F.2008. Measurement of maximal inspiratory pressure in ventilated childrenPediatr. Pulmonol.431085-1091. Harikumar, G., Moxham, J., Greenough, A., and Rafferty, G.F. (2008). Measurement of maximal inspiratory pressure in ventilated children. Pediatr. Pulmonol. 43, 1085–1091.
Hauswirth W.W.Aleman T.S.Kaushal S. et al.2008. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trialHum. Gene Ther.19979-990. Hauswirth, W.W., Aleman, T.S., Kaushal, S., et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum. Gene Ther. 19, 979–990.
Hirschhorn R.Reuser A.J.2001. Glycogen storage disease type II: (acid maltase) deficiency. In The Metabolic and Molecular Bases of Inherited Disease (OMMBID)C. ScriverA. BeaudetW. SlyD. ValleB. VogelsteinMcGraw-HillNew York3389-3420. Hirschhorn, R., and Reuser, A.J. (2001). Glycogen storage disease type II: (acid maltase) deficiency. In The Metabolic and Molecular Bases of Inherited Disease (OMMBID). C. Scriver, A. Beaudet, W. Sly, D. Valle, and B. Vogelstein, eds. (McGraw-Hill, New York) pp. 3389–3420.
Huang C.H.Martin A.D.Davenport P.W.2003. Effect of inspiratory muscle strength training on inspiratory motor drive and RREP early peak componentsJ. Appl. Physiol.94462-468. Huang, C.H., Martin, A.D., and Davenport, P.W. (2003). Effect of inspiratory muscle strength training on inspiratory motor drive and RREP early peak components. J. Appl. Physiol. 94, 462–468.
Jaber S.Petrof B.J.Jung B. et al.2011. Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humansAm. J. Respir. Crit. Care Med.183364-371. Jaber, S., Petrof, B.J., Jung, B., et al. (2011). Rapidly progressive diaphragmatic weakness and injury during mechanical ventilation in humans. Am. J. Respir. Crit. Care Med. 183, 364–371.
Kikuchi T.Yang H.W.Pennybacker M. et al.1998. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quailJ. Clin. Invest.101827-833. Kikuchi, T., Yang, H.W., Pennybacker, M., et al. (1998). Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J. Clin. Invest. 101, 827–833.
Kishnani P.S.Hwu W.L.Mandel H. et al.2006. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe diseaseJ. Pediatr.148671-676. Kishnani, P.S., Hwu, W.L., Mandel, H., et al. (2006). A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J. Pediatr. 148, 671–676.
Kishnani P.S.Corzo D.Nicolino M. et al.2007. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe diseaseNeurology6899-109. Kishnani, P.S., Corzo, D., Nicolino, M., et al. (2007). Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99–109.
Lee K.Z.Qiu K.Sandhu M.S. et al.2011. Hypoglossal neuropathology and respiratory activity in pompe mice. FrontPhysiol.231. Lee, K.Z., Qiu, K., Sandhu, M.S., et al. (2011). Hypoglossal neuropathology and respiratory activity in pompe mice. Front. Physiol. 2, 31.
Levine S.Nguyen T.Taylor N. et al.2008. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humansN. Engl. J. Med.3581327-1335. Levine, S., Nguyen, T., Taylor, N., et al. (2008). Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N. Engl. J. Med. 358, 1327–1335.
Louboutin J.P.Wang L.Wilson J.M.2005. Gene transfer into skeletal muscle using novel AAV serotypesJ. Gene Med.7442-451. Louboutin, J.P., Wang, L., and Wilson, J.M. (2005). Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7, 442–451.
Mah C.Cresawn K.O.Fraites T.J. Jr. et al.2005. Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectorsGene Ther.121405-1409. Mah, C., Cresawn, K.O., Fraites, T.J., Jr., et al. (2005). Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther. 12, 1405–1409.
Mah C.Pacak C.A.Cresawn K.O. et al.2007. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectorsMol. Ther.15501-507. Mah, C., Pacak, C.A., Cresawn, K.O., et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol. Ther. 15, 501–507.
Mah C.S.Falk D.J.Germain S.A. et al.2010. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established diseaseMol. Ther.18502-510. Mah, C.S., Falk, D.J., Germain, S.A., et al. (2010). Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol. Ther. 18, 502–510.
Mancall E.L.Aponte G.E.Berry R.G.1965. Pompe's disease (diffuse glycogenosis) with neuronal storageJ. Neuropathol. Exp. Neurol.2485-96. Mancall, E.L., Aponte, G.E., and Berry, R.G. (1965). Pompe's disease (diffuse glycogenosis) with neuronal storage. J. Neuropathol. Exp. Neurol. 24, 85–96.
Mantilla C.B.Seven Y.B.Zhan W.Z.Sieck G.C.2010. Diaphragm motor unit recruitment in ratsRespir. Physiol. Neurobiol.173101-106. Mantilla, C.B., Seven, Y.B., Zhan, W.Z., and Sieck, G.C. (2010). Diaphragm motor unit recruitment in rats. Respir. Physiol. Neurobiol. 173, 101–106.
Martin A.D.Smith B.K.Davenport P. et al.2011. Inspiratory muscle strength training improves weaning outcome in failure to wean patients: a randomized trial. CritCare15R84. Martin, A.D., Smith, B.K., Davenport, P., et al. (2011). Inspiratory muscle strength training improves weaning outcome in failure to wean patients: a randomized trial. Crit. Care 15, R84.
Mendell J.R.Rodino-Klapac L.R.Rosales X.Q. et al.2010. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2DAnn. Neurol.68629-638. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., et al. (2010). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 68, 629–638.
Nicolino M.Byrne B.Wraith J.E. et al.2009. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe diseaseGenet. Med.11210-219. Nicolino, M., Byrne, B., Wraith, J.E., et al. (2009). Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 11, 210–219.
Nicot F.Hart N.Forin V. et al.2006. Respiratory muscle testing: a valuable tool for children with neuromuscular disordersAm. J. Respir. Crit. Care Med.17467-74. Nicot, F., Hart, N., Forin, V., et al. (2006). Respiratory muscle testing: a valuable tool for children with neuromuscular disorders. Am. J. Respir. Crit. Care Med. 174, 67–74.
Poirier A.Campbell-Thompson M.Tang Q. et al.2004. Toxicology and biodistribution studies of a recombinant adeno-associated virus 2 (rAAV2)-Alpha-1-antitrypsin (AAT) vectorPreClinica243-51. Poirier, A., Campbell-Thompson, M., Tang, Q., et al. (2004). Toxicology and biodistribution studies of a recombinant adeno-associated virus 2 (rAAV2)-Alpha-1-antitrypsin (AAT) vector. PreClinica 2, 43–51.
Ponder K.P.2011. Merry Christmas for patients with hemophilia BN. Engl. J. Med.3652424-2425. Ponder, K.P. (2011). Merry Christmas for patients with hemophilia B. N. Engl. J. Med. 365, 2424–2425.
Raben N.Plotz P.Byrne B.J.2002. Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)Curr. Mol. Med.2145-66. Raben, N., Plotz, P., and Byrne, B.J. (2002). Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr. Mol. Med. 2, 145–66.
Ramirez-Sarmiento A.Orozco-Levi M.Guell R. et al.2002. Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomesAm. J. Respir. Crit. Care Med.1661491-1497. Ramirez-Sarmiento, A., Orozco-Levi, M., Guell, R., et al. (2002). Inspiratory muscle training in patients with chronic obstructive pulmonary disease: structural adaptation and physiologic outcomes. Am. J. Respir. Crit. Care Med. 166, 1491–1497.
Rohrbach M.Klein A.Kohli-Wiesner A. et al.2010. CRIM-negative infantile Pompe disease: 42-month treatment outcomeJ. Inherit. Metab. Dis.33751-757. Rohrbach, M., Klein, A., Kohli-Wiesner, A., et al. (2010). CRIM-negative infantile Pompe disease: 42-month treatment outcome. J. Inherit. Metab. Dis. 33, 751–757.
Rosenthal M.Bain S.H.Cramer D. et al.1993. Lung function in white children aged 4 to 19 years: I—SpirometryThorax48794-802. Rosenthal, M., Bain, S.H., Cramer, D., et al. (1993). Lung function in white children aged 4 to 19 years: I—Spirometry. Thorax 48, 794–802.
Shea L.Raben N.2009. Autophagy in skeletal muscle: implications for Pompe diseaseInt. J. Clin. Pharmacol. Ther.471S42-S47. Shea, L., and Raben, N. (2009). Autophagy in skeletal muscle: implications for Pompe disease. Int. J. Clin. Pharmacol. Ther. 47 Suppl 1, S42–S47.
Sieck G.C.1994. Physiological effects of diaphragm muscle denervation and disuseClin. Chest Med.15641-659. Sieck, G.C. (1994). Physiological effects of diaphragm muscle denervation and disuse. Clin. Chest Med. 15, 641–659.
Sieck G.C.Fournier M.1989. Diaphragm motor unit recruitment during ventilatory and nonventilatory behaviorsJ. Appl. Physiol.662539-2545. Sieck, G.C., and Fournier, M. (1989). Diaphragm motor unit recruitment during ventilatory and nonventilatory behaviors. J. Appl. Physiol. 66, 2539–2545.
Smith B.K.Bleiweis M.S.Zauhar J.Martin A.D.2011. Inspiratory muscle training in a child with nemaline myopathy and organ transplantationPediatr. Crit. Care Med.12e94-e98. Smith, B.K., Bleiweis, M.S., Zauhar, J., and Martin, A.D. (2011). Inspiratory muscle training in a child with nemaline myopathy and organ transplantation. Pediatr. Crit. Care Med. 12, e94–e98.
Smith B.K.Bleiweis M.S.Neel C.R.Martin A.D.2013. Inspiratory muscle strength training in infants with congenital heart disease and prolonged mechanical ventilation: a case reportPhys. Ther.93229-236. Smith, B.K., Bleiweis, M.S., Neel, C.R., and Martin, A.D. (2013). Inspiratory muscle strength training in infants with congenital heart disease and prolonged mechanical ventilation: a case report. Phys. Ther. 93, 229–236.
Song S.Scott-Jorgensen M.Wang J. et al.2002. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspectsMol. Ther.6329-335. Song, S., Scott-Jorgensen, M., Wang, J., et al. (2002). Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol. Ther. 6, 329–335.
Stein R.Selvadurai H.Coates A. et al.2003. Determination of maximal voluntary ventilation in children with cystic fibrosisPediatr. Pulmonol.35467-471. Stein, R., Selvadurai, H., Coates, A., et al. (2003). Determination of maximal voluntary ventilation in children with cystic fibrosis. Pediatr. Pulmonol. 35, 467–471.
Truwit J.D.Marini J.J.1992. Validation of a technique to assess maximal inspiratory pressure in poorly cooperative patientsChest1021216-1219. Truwit, J.D., and Marini, J.J. (1992). Validation of a technique to assess maximal inspiratory pressure in poorly cooperative patients. Chest 102, 1216–1219.
van der Ploeg A.T.Reuser A.J.2008. Pompe's diseaseLancet3721342-1353. van der Ploeg, A.T., and Reuser, A.J. (2008). Pompe's disease. Lancet 372, 1342–1353.
van Gelder C.M.Van Capelle C.I.Ebbink B.J. et al.2012. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapyJ. Inherit. Metab. Dis.35505-511. van Gelder, C.M., Van Capelle, C.I., Ebbink, B.J., et al. (2012). Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J. Inherit. Metab. Dis. 35, 505–511.
Zapletal A.Chalupova J.2003. Forced expiratory parameters in healthy preschool children (3–6 years of age)Pediatr. Pulmonol.35200-207. Zapletal, A., and Chalupova, J. (2003). Forced expiratory parameters in healthy preschool children (3–6 years of age). Pediatr. Pulmonol. 35, 200–207.
Zifko U.Young B.G.Bolton C.F.1997. Electrophysiological monitoring in neurological respiratory insufficiencyJ. Neurol. Neurosurg. Psychiatry62299-300. Zifko, U., Young, B.G., and Bolton, C.F. (1997). Electrophysiological monitoring in neurological respiratory insufficiency. J. Neurol. Neurosurg. Psychiatry 62, 299–300.
Information & Authors
Information
Published In
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published in print: June 2013
Published online: 9 April 2013
Accepted: 29 March 2013
Received: 22 December 2012
Topics
Authors
Author Disclosure Statement
B.J.B., C.S.M., The Johns Hopkins University, and the University of Florida could be entitled to patent royalties for inventions described in this article. B.K.S., S.W.C., T.J.C., L.A.L., A.D.M., D.D.F., B.D.C., N.C., D.P., S.I., and N.D. have no conflicts to report.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.